- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
argenx NV ADR (ARGX)
argenx NV ADR stock price live, this page displays NASDAQ ARGX stock exchange data. View the ARGX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the argenx NV ADR real time stock price chart below.
What Is the argenx NV ADR Stock Price Today?
The argenx NV ADR stock price today is 661.97.
What Is the Stock Symbol for argenx NV ADR?
The stock symbol for argenx NV ADR is ""ARGX.""
What Stock Exchange Does argenx NV ADR Trade On?
argenx NV ADR is listed and trades on the NASDAQ stock exchange.
Is argenx NV ADR a Good Stock to Buy?
Determining whether argenx NV ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARGX quote. (ISIN: US04016X1019)
What Is the argenx NV ADR Stock Price Today?
The argenx NV ADR stock price today is 661.97.
What Is the Stock Symbol for argenx NV ADR?
The stock symbol for argenx NV ADR is ""ARGX.""
What Stock Exchange Does argenx NV ADR Trade On?
argenx NV ADR is listed and trades on the NASDAQ stock exchange.
Is argenx NV ADR a Good Stock to Buy?
Determining whether argenx NV ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARGX quote. (ISIN: US04016X1019)
661.97
+1.00(+0.15%)
Real-time Data·
Fair Value
An estimate of a argenx ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
659.26
670.71
52 wk Range
510.06
696.21
ARGX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ARGX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a argenx ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
659.26670.71
52 wk Range
510.06696.21
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARGX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a argenx ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
804.56
Upside
+21.54%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Argenx receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Argen-X receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Argenx receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Argenx receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Argen-X receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Argenx receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Argen-X receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Argen-X receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
argenx NV ADR Company Profile
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
argenx NV ADR SWOT Analysis
Vyvgart's Triumph | Explore argenx's meteoric rise in biotech, driven by Vyvgart's success in treating autoimmune diseases and its recent approval for CIDP treatment |
Financial Milestones | Delve into argenx's robust financial health, with a market cap of $39.27B, 85.56% revenue growth, and projected profitability by fiscal year 2025 |
Market Dominance | Learn how argenx is solidifying its position in gMG and CIDP markets, with over 50% of new Vyvgart patients switching from oral treatments |
Future Horizons | Analysts project long-term revenue potential of $8B by 2033, with price targets ranging from $468 to $725, reflecting confidence in argenx's growth |
argenx NV ADR Earnings Call Summary for Q2/2025
- Q2 EPS of $6.32, doubling expectations; revenue at $1.74B, 98.56% above forecast; stock surged 12.51% pre-market
- Vyvgart's success drove 97% YoY product sales growth to $949M; treated 15,000 patients globally
- Cash balance increased to $3.9B; company maintains strong financial health with 3.57/5 InvestingPro score
- Expects data from six Phase 3 and six Phase 2 trials in next 18 months; aims for 50,000 patients by 2030
- CEO emphasizes Vision 2030 for long-term value; Q4 2025 revenue projected at $1.18B
Last Updated: 21/08/2025, 05:34
Read Full TranscriptCompare ARGX to Peers and Sector
Metrics to compare | ARGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARGXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 32.1x | −1.6x | −0.6x | |
PEG Ratio | 0.05 | 0.00 | 0.00 | |
Price/Book | 6.7x | 1.7x | 2.6x | |
Price / LTM Sales | 13.2x | 4.6x | 3.3x | |
Upside (Analyst Target) | 19.7% | 60.3% | 39.5% | |
Fair Value Upside | Unlock | 8.6% | 4.9% | Unlock |
Analyst Ratings
21 Buy
1 Hold
0 Sell
Ratings:
22 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 804.56
(+21.54% Upside)
Earnings
Latest Release
Jul 31, 2025
EPS / Forecast
6.32 / 3.06
Revenue / Forecast
1.74B / 876.30M
People Also Watch
FAQ
What Stock Exchange Does argenx ADR Trade On?
argenx ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for argenx ADR?
The stock symbol for argenx ADR is "ARGX."
What Is the argenx ADR Market Cap?
As of today, argenx ADR market cap is 40.82B.
What Is argenx ADR's Earnings Per Share (TTM)?
The argenx ADR EPS (TTM) is 21.10.
When Is the Next argenx ADR Earnings Date?
argenx ADR will release its next earnings report on 29 Oct 2025.
From a Technical Analysis Perspective, Is ARGX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has argenx ADR Stock Split?
argenx ADR has split 0 times.
How Many Employees Does argenx ADR Have?
argenx ADR has 1599 employees.
What is the current trading status of argenx ADR (ARGX)?
As of 21 Aug 2025, argenx ADR (ARGX) is trading at a price of 661.97, with a previous close of 660.97. The stock has fluctuated within a day range of 659.26 to 670.71, while its 52-week range spans from 510.06 to 696.21.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.